Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission
Clinical trial NCT05502250 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05502250
- Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-14
- Primary completion
- 2028-03-01
- Enrollment
- 75
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.